Dr. C. Warren Olanow “Synagile Announces Positive Results from Phase 2a Trial of Continuous Intraoral LD-CD Therapy”
Positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD) were released today. "Motor complications, and specifically OFF time, can have a profoundly negative impact on the lives of Parkinson's disease patients," said Warren Olanow, MD, FRCPC, co-principal investigator of the study and chairman emeritus of the department of neurology at the Icahn School of Medicine at Mount Sinai. “A safe, convenient, noninvasive, nonsurgical, oral levodopa therapy would be a major advance in treatment.” Learn more
New Research Reveals Autism Risk Genes Are Shared Across Ancestries
Mar 30, 2026 View All Press Releases
